<DOC>
	<DOCNO>NCT02024308</DOCNO>
	<brief_summary>The purpose study determine whether Fludarabine combination cytarabine effective high-dose cytarabine post-remission therapy patient AML1-ETO acute myeloid leukemia .</brief_summary>
	<brief_title>AML1-ETO Acute Myeloid Leukemia With Fludarabine Cytarabine Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Clinical laboratory diagnosis AML1ETO positive acute myeloid leukemia In status complete remission one two course induction therapy DA ( Daunorubicin 60mg/m2/d 3 day , cytarabine 100mg/m2/d 57days ) regimen ECOG ( Eastern Cooperative Oncology Group ) score : &lt; 2 Serious liver/ kidney dysfunction Cardiac function level : 2 Female pregnancy lactation With serious infection disease disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>acute myeloid leukemia ,</keyword>
	<keyword>AML1-ETO fusion protein ,</keyword>
	<keyword>Fludarabine ,</keyword>
	<keyword>recurrence</keyword>
</DOC>